Telix Pharmaceuticals (Australia) Buy Hold or Sell Recommendation
| TLX Stock | 25.74 0.80 3.21% |
Assuming the 90 days trading horizon and your way above-average risk tolerance, our recommendation regarding Telix Pharmaceuticals is 'Strong Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Telix Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Telix Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Telix Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Telix and provide practical buy, sell, or hold advice based on investors' constraints. Telix Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Telix |
Execute Telix Pharmaceuticals Buy or Sell Advice
The Telix recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Telix Pharmaceuticals. Macroaxis does not own or have any residual interests in Telix Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Telix Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Solid | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Telix Pharmaceuticals Trading Alerts and Improvement Suggestions
| Telix Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| About 41.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Telix Pharmaceuticals Updates Securities Policy Amid Market Interest - TipRanks |
Telix Pharmaceuticals Returns Distribution Density
The distribution of Telix Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Telix Pharmaceuticals' future price movements. The chart of the probability distribution of Telix Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Telix Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Telix Pharmaceuticals returns is essential to provide solid investment advice for Telix Pharmaceuticals.
| Mean Return | 0.58 | Value At Risk | -3.24 | Potential Upside | 4.04 | Standard Deviation | 2.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Telix Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Telix Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 18.8M | 33.3M | (55.9M) | 94.3M | 6.9M | 6.6M | |
| Net Borrowings | (1.2M) | (904K) | (936K) | 1.7M | 2.0M | 2.1M | |
| Depreciation | 4.2M | 4.9M | 5.2M | 5.4M | 6.9M | 7.3M | |
| Other Non Cash Items | 9.7M | 18.7M | 31.5M | 41.0M | 60.5M | 63.5M | |
| Capital Expenditures | 468K | 322K | 1.3M | 13.9M | 10.8M | 11.3M | |
| Net Income | (27.9M) | (44.9M) | (80.5M) | (104.1M) | 5.2M | 5.5M | |
| Change To Netincome | 659K | 10.2M | 18.6M | 35.7M | 41.1M | 43.2M | |
| Investments | (468K) | (1.1M) | (2.7M) | (17.0M) | (25.5M) | (24.2M) | |
| Free Cash Flow | (23.8M) | 1.6M | (60.7M) | (77.8M) | 13.1M | 13.7M | |
| End Period Cash Flow | 44.6M | 77.9M | 22.0M | 116.3M | 123.2M | 72.1M |
Telix Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Telix Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Telix Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Telix stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | 0.35 | |
σ | Overall volatility | 1.90 | |
Ir | Information ratio | 0.25 |
Telix Pharmaceuticals Volatility Alert
Telix Pharmaceuticals currently demonstrates below-average downside deviation. It has Information Ratio of 0.25 and Jensen Alpha of 0.56. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Telix Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Telix Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Telix Pharmaceuticals Fundamentals Vs Peers
Comparing Telix Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Telix Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Telix Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Telix Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Telix Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Telix Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Telix Pharmaceuticals to competition |
| Fundamentals | Telix Pharmaceuticals | Peer Average |
| Return On Equity | 0.2 | -0.31 |
| Return On Asset | 0.0797 | -0.14 |
| Profit Margin | 0.08 % | (1.27) % |
| Operating Margin | 0.09 % | (5.51) % |
| Current Valuation | 8.52 B | 16.62 B |
| Shares Outstanding | 334.72 M | 571.82 M |
| Shares Owned By Insiders | 41.42 % | 10.09 % |
| Shares Owned By Institutions | 17.88 % | 39.21 % |
| Price To Book | 21.33 X | 9.51 X |
| Price To Sales | 13.01 X | 11.42 X |
| Revenue | 496.66 M | 9.43 B |
| Gross Profit | 98.54 M | 27.38 B |
| EBITDA | 22.97 M | 3.9 B |
| Net Income | 5.21 M | 570.98 M |
| Total Debt | 17.45 M | 5.32 B |
| Book Value Per Share | 1.21 X | 1.93 K |
| Cash Flow From Operations | 23.88 M | 971.22 M |
| Earnings Per Share | 0.15 X | 3.12 X |
| Target Price | 25.62 | |
| Beta | 2.38 | -0.15 |
| Market Capitalization | 8.4 B | 19.03 B |
| Total Asset | 398.3 M | 29.47 B |
| Retained Earnings | (263.67 M) | 9.33 B |
| Working Capital | 67.44 M | 1.48 B |
| Net Asset | 398.3 M |
Telix Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Telix . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 72561.61 | |||
| Daily Balance Of Power | 0.6957 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 25.23 | |||
| Day Typical Price | 25.4 | |||
| Price Action Indicator | 0.91 | |||
| Period Momentum Indicator | 0.8 |
About Telix Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Telix Pharmaceuticals? Buying financial instruments such as Telix Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Telix Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Defense Thematic Idea Now
Defense
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Defense theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Defense Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.